| Drug | Antibody type | Notable side effects | Study (phase) |
| Anti-CTLA-4 antibodies | | | | Ipilimumab | IgG1 | Diarrhea, colitis, fatigue, transaminitis, hypophysitis. | I; II | Tremelimumab | IgG2 | Diarrhea, fatigue, nausea, vomiting, anorexia, rash | I |
| Anti-PD-1 antibodies | | | | Nivolumab | IgG4 | Pneumonitis, lymphopenia, fatigue, diarrhea, hepatitis, renal insufficiency | I; II | Pembrolizumab | IgG4-kappa | Pneumonitis, fatigue, thyroid problems | I |
| Anti-PD-L1 antibodies | | | | BMS-936559 | IgG4 | Fatigue, hyperglycemia, infusion reaction, endocrinopathies, adrenal insufficiency, myasthenia gravis | I; II | MEDI4736 | IgG1-kappa | Diarrhea, fatigue, rash, vomiting | I | MPDL33280A | IgG4 | Hyperglycemia, hypophysitis, pericardial effusion, fatigue | I | MSB0010718C | IgG1 | Laboratory abnormalities, creatine kinase increase, myositis, myocarditis | I; II |
|
|